Obstet Gynecol Sci.  2025 Mar;68(2):93-108. 10.5468/ogs.24255.

The impact of GABA and GABAergic pathway in polycystic ovary syndrome: a systematic review

• Motafeghi F
• Amiri M
• Noroozzadeh M
• Tehrani FR

• KMID: 2565673
• DOI: http://doi.org/10.5468/ogs.24255

Abstract

Emerging evidence indicates that dysfunction of the gamma-aminobutyric acid (GABA)ergic pathway may contribute to the pathophysiology of polycystic ovary syndrome (PCOS), and GABA demonstrates potential in the management of PCOS symptoms. This systematic review aimed to determine the role of the GABAergic pathway in PCOS and evaluate the impact of GABA on improving the condition. Web of Science, Embase, Scopus, Cochrane, and PubMed databases were systematically searched for experimental studies, clinical trials, animal studies, and cellular investigations. The search was conducted for relevant English-language manuscripts, published up to February 2024, using keywords, such as "polycystic ovary syndrome", PCOS, "gamma-aminobutyric acid" and GABA. Quality assessment of the included studies was performed using the Cochrane Collaboration's tool and the Newcastle-Ottawa scale. The results indicate that GABAergic dysfunction adversely affects gonadotrophin-releasing hormone neuronal activity, leading to hormonal imbalances and reproductive issues. Prenatal androgen exposure and kisspeptin signaling influence GABAergic transmission to GnRH neurons, thereby linking GABA to the pathogenesis of PCOS. Additionally, GABAergic signaling affects peripheral tissues relevant to PCOS, including the immune system, gut-brain axis, and ovaries. GABA supplementation has demonstrated potential benefits in enhancing metabolic and reproductive health, such as reducing insulin resistance and modulating sex hormone levels, as supported by animal models and clinical studies involving females with PCOS. The GABAergic signaling pathway may represent a promising therapeutic target for the management of PCOS. Nevertheless, further studies are required to validate these findings and deepen our understanding of the role of GABA in the pathogenesis and treatment of PCOS.

Keyword

Polycystic ovary syndrome; Gamma-aminobutyric acid; Gonadotropin-releasing hormone

Figure

• 

  Fig. 1 Article flow diagram. ICTRP, international clinical trials registry platform.

Reference

References

1. Noroozzadeh M, Behboudi-Gandevani S, Zadeh-Vakili A, Ramezani Tehrani F. Hormone-induced rat model of polycystic ovary syndrome: a systematic review. Life Sciences. 2017; 191:259–72.

2. Zuchelo LTS, Alves MS, Baracat EC, Sorpreso ICE, Soares JM Jr. Menstrual pattern in polycystic ovary syndrome and hypothalamic-pituitary-ovarian axis immaturity in adolescents: a systematic review and meta-analysis. Gynecol Endocrinol. 2024; 40:2360077.

3. Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013; 38:336–55.

4. Devarbhavi P, Telang L, Vastrad B, Tengli A, Vastrad C, Kotturshetti I. Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules. Reprod Biol Endocrinol. 2021; 19:31.

5. Walters KA, Moreno-Asso A, Stepto NK, Pankhurst MW, Rodriguez Paris V, Rodgers RJ. Key signalling pathways underlying the aetiology of polycystic ovary syndrome. J Endocrinol. 2022; 255:R1–26.

6. Rahimi Rick E, Mahmoudi F, khazali H, Asadi A, Ghowsi M. A role for GABA agonist in controlling the reproduction of female rats via hypothalamic ghrelin, kisspeptin, and RFRP-3 gene expression. Iran J Vet Sci Technol. 2021; 13:42–7.

7. Moore AM, Campbell RE. The neuroendocrine genesis of polycystic ovary syndrome: a role for arcuate nucleus GABA neurons. J Steroid Biochem Mol Biol. 2016; 160:106–17.

8. Mikhael S, Punjala-Patel A, Gavrilova-Jordan L. Hypothalamic-pituitary-ovarian axis disorders impacting female fertility. Biomedicines. 2019; 7:5.

9. Cullinan WE, Ziegler DR, Herman JP. Functional role of local GABAergic influences on the HPA axis. Brain Struct Funct. 2008; 213:63–72.

10. Radwan RA, Abuelezz NZ, Abdelraouf SM, Bakeer EM, Rahman AAAE. Decreased serum level of gamma-amino butyric acid in egyptian infertile females with polycystic ovary syndrome is correlated with dyslipidemia, total testosterone and 25(OH) vitamin D levels. J Med Biochem. 2019; 38:512–8.

11. Sucquart IE, Coyle C, Rodriguez Paris V, Prescott M, Glendining KA, Potapov K, et al. Investigating GABA neuron-specific androgen receptor knockout in two hyperandrogenic models of PCOS. Endocrinology. 2024; 165:bqae060.

12. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021; 372:n160.

13. Watanabe Y, Fisher L, Campbell RE, Jasoni CL. Defining potential targets of prenatal androgen excess: expression analysis of androgen receptor on hypothalamic neurons in the fetal female mouse brain. J Neuroendocrinol. 2023; 35:e13302.

14. Bhattarai P, Rijal S, Bhattarai JP, Cho DH, Han SK. Suppression of neurotransmission on gonadotropin-releasing hormone neurons in letrozole-induced polycystic ovary syndrome: a mouse model. Front Endocrinol (Lausanne). 2023; 13:1059255.

15. Watanabe Y, Prescott M, Campbell RE, Jasoni CL. Prenatal androgenization causes expression changes of progesterone and androgen receptor mRNAs in the arcuate nucleus of female mice across development. J Neuroendocrinol. 2021; 33:e13058.

16. Sarahian N, Sarvazad H, Sajadi E, Rahnejat N, Eskandari Roozbahani N. Investigation of common risk factors between polycystic ovary syndrome and Alzheimer’s disease: a narrative review. Reprod Health. 2021; 18:156.

17. Silva MSB, Desroziers E, Hessler S, Prescott M, Coyle C, Herbison AE, et al. Activation of arcuate nucleus GABA neurons promotes luteinizing hormone secretion and reproductive dysfunction: implications for polycystic ovary syndrome. EBioMedicine. 2019; 44:582–96.

18. Coyle CS, Prescott M, Handelsman DJ, Walters KA, Campbell RE. Chronic androgen excess in female mice does not impact luteinizing hormone pulse frequency or putative GABAergic inputs to GnRH neurons. J Neuroendocrinol. 2022; 34:e13110.

19. Berg T, Silveira MA, Moenter SM. Prepubertal development of GABAergic transmission to gonadotropin-releasing hormone (GnRH) neurons and postsynaptic response are altered by prenatal androgenization. J Neurosci. 2018; 38:2283–93.

20. Sati A, Prescott M, Holland S, Jasoni CL, Desroziers E, Campbell RE. Morphological evidence indicates a role for microglia in shaping the PCOS-like brain. J Neuroendocrinol. 2021; 33:e12999.

21. Marshall CJ, Prescott M, Campbell RE. Investigating the NPY/AgRP/GABA to GnRH neuron circuit in prenatally androgenized PCOS-like mice. J Endocr Soc. 2020; 4:bvaa129.

22. Dulka EA, Defazio RA, Moenter SM. Chemogenetic suppression of gnrh neurons during pubertal development can alter adult gnrh neuron firing rate and reproductive parameters in female mice. eNeuro. 2020; 7:ENEURO. 0223-202020.

23. Sullivan SD, Moenter SM. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci U S A. 2004; 101:7129–34.

24. Porter DT, Moore AM, Cobern JA, Padmanabhan V, Goodman RL, Coolen LM, et al. Prenatal testosterone exposure alters GABAergic synaptic inputs to GnRH and KNDy neurons in a sheep model of polycystic ovarian syndrome. Endocrinology. 2019; 160:2529–42.

25. Mahesh VB. Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective. Am J Physiol Endocrinol Metab. 2012; 302:E4–18.

26. Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016; 7:10055.

27. Campbell R. Dissecting the role of specific brain circuits in polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2018; 89:30–1.

28. Silva MS, Prescott M, Campbell RE. Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS. JCI Insight. 2018; 3:e99405.

29. Stener-Victorin E. Update on animal models of polycystic ovary syndrome. Endocrinology. 2022; 163:bqac164.

30. Osuka S, Nakanishi N, Murase T, Nakamura T, Goto M, Iwase A, et al. Animal models of polycystic ovary syndrome: a review of hormone-induced rodent models focused on hypothalamus-pituitary-ovary axis and neuropeptides. Reprod Med Biol. 2018; 18:151–60.

31. Eepho OI, Bashir AM, Oniyide AA, Aturamu A, Owolabi OV, Ajadi IO, et al. Modulation of GABA by sodium butyrate ameliorates hypothalamic inflammation in experimental model of PCOS. BMC Neurosci. 2023; 24:62.

32. Moore AM, Prescott M, Marshall CJ, Yip SH, Campbell RE. Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome. Proc Natl Acad Sci U S A. 2015; 112:596–601.

33. Gao Z, Ma X, Liu J, Ge Y, Wang L, Fu P, et al. Troxerutin protects against DHT-induced polycystic ovary syndrome in rats. J Ovarian Res. 2020; 13:106.

34. Ullah A, Jahan S, Razak S, Pirzada M, Ullah H, Almajwal A, et al. Protective effects of GABA against metabolic and reproductive disturbances in letrozole induced polycystic ovarian syndrome in rats. J Ovarian Res. 2017; 10:62.

35. Sullivan SD, Moenter SM. Neurosteroids alter gamma-aminobutyric acid postsynaptic currents in gonadotropin-releasing hormone neurons: a possible mechanism for direct steroidal control. Endocrinology. 2003; 144:4366–75.

36. Liang Z, Di N, Li L, Yang D. Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome. J Endocrinol Invest. 2021; 44:1727–37.

37. Jin L, Yu J, Chen Y, Pang H, Sheng J, Huang H. Polycystic ovary syndrome and risk of five common psychiatric disorders among European women: a two-sample mendelian randomization study. Front Genet. 2021; 12:689897.

38. Aydogan Kirmizi D, Baser E, Onat T, Demir Caltekin M, Yalvac ES, Kara M, et al. Sexual function and depression in polycystic ovary syndrome: is it associated with inflammation and neuromodulators? Neuropeptides. 2020; 84:102099.

39. Radwan RA, Abuelezz NZ, Abdelraouf SM, Bakeert EM, Abd El Rahman AA. Decreased serum level of gamma-amino butyric acid in egyptian infertile females with polycystic ovary syndrome is correlated with dyslipidemia, total testosterone and 25(OH) vitamin D levels. J Med Biochem. 2019; 38:512.

40. Kawwass JF, Sanders KM, Loucks TL, Rohan LC, Berga SL. Increased cerebrospinal fluid levels of GABA, testosterone and estradiol in women with polycystic ovary syndrome. Hum Reprod. 2017; 32:1450–6.

41. Ye Z, Zhang C, Wang S, Zhang Y, Li R, Zhao Y, et al. Amino acid signatures in relation to polycystic ovary syndrome and increased risk of different metabolic disturbances. Reprod Biomed Online. 2022; 44:737–46.

42. Silva MSB, Campbell RE. Polycystic ovary syndrome and the neuroendocrine consequences of androgen excess. Compr Physiol. 2022; 12:3347–69.

43. Hedström H, Bäckström T, Bixo M, Nyberg S, Wang M, Gideonsson I, et al. Women with polycystic ovary syndrome have elevated serum concentrations of and altered GABA(A) receptor sensitivity to allopregnanolone. Clin Endocrinol (Oxf). 2015; 83:643–50.

44. Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic ovarian disease [Internet]. Treasure Island (FL): StatPearls Publishing;c2022. [cited 2022 Nov 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459251/.

45. Watanabe M, Fukuda A, Nabekura J. The role of GABA in the regulation of GnRH neurons. Front Neurosci. 2014; 8:387.

46. Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet. 2022; 39:2439–73.

47. Sullivan SD, Moenter SM. GABAergic integration of progesterone and androgen feedback to gonadotropin-releasing hormone neurons. Biol Reprod. 2005; 72:33–41.

48. Liao B, Qiao J, Pang Y. Central regulation of PCOS: abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Front Endocrinol (Lausanne). 2021; 12:667422.

49. Prashar V, Arora T, Singh R, Sharma A, Parkash J. Hypothalamic kisspeptin neurons: integral elements of the GnRH system. Reprod Sci. 2023; 30:802–22.

50. Kaur S, Singh S, Arora A, Ram P, Kumar S, Kumar P, et al. Pharmacology of GABA and its receptors. Kumar P, Deb PK, editors. Frontiers in pharmacology of neurotransmitters. 1st ed. Singapore: Springer;2020. p. 241–92.

51. Han SK, Abraham IM, Herbison AE. Effect of GABA on GnRH neurons switches from depolarization to hyperpolarization at puberty in the female mouse. Endocrinology. 2002; 143:1459–66.

52. Spergel DJ. Modulation of gonadotropin-releasing hormone neuron activity and secretion in mice by non-peptide neurotransmitters, gasotransmitters, and gliotransmitters. Front Endocrinol (Lausanne). 2019; 10:329.

53. Penatti CA, Davis MC, Porter DM, Henderson LP. Altered GABAA receptor-mediated synaptic transmission disrupts the firing of gonadotropin-releasing hormone neurons in male mice under conditions that mimic steroid abuse. J Neurosci. 2010; 30:6497–506.

54. Alizadeh M, Karandish M, Asghari Jafarabadi M, Heidari L, Nikbakht R, Babaahmadi Rezaei H, et al. Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Nutr Metab (Lond). 2021; 18:57.

55. Yang CY, He L. Neuroprotective effects of sinapine on PC12 cells apoptosis induced by sodium dithionite. Chin J Nat Med. 2008; 6:205–9.

56. Wang R. GABAergic transmission and inhibitory postsynaptic potentials: implications for neurological disorders. Neurophysiol Res. 2023; 5:142.

57. Nava-Mesa MO, Jiménez-Díaz L, Yajeya J, Navarro-Lopez JD. GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer’s disease. Front Cell Neurosci. 2014; 8:167.

58. Mizuno S, Iijima R, Ogishima S, Kikuchi M, Matsuoka Y, Ghosh S, et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease. BMC Syst Biol. 2012; 30:52.

59. Blatt GJ, Soghomonian JJ, Yip J. Glutamic acid decarboxylase (GAD) as a biomarker of GABAergic activity in autism: impact on cerebellar circuitry and function. Blatt GJ, editor. The neurochemical basis of autism: from molecules to minicolumns. 1st ed. Boston (MA): Springer US;2010. p. 95–111.

60. Zuppichini MD, Hamlin AM, Zhou Q, Kim E, Rajagopal S, Beltz AM, et al. GABA levels decline with age: a longitudinal study. Imaging Neuroscience. 2024; 2:1–15.

61. Ethiraj J, Palpagama TH, Turner C, van der Werf B, Waldvogel HJ, Faull RLM, et al. The effect of age and sex on the expression of GABA signaling components in the human hippocampus and entorhinal cortex. Sci Rep. 2021; 11:21470.

62. Xu Y, Zhao M, Han Y, Zhang H. GABAergic inhibitory interneuron deficits in Alzheimer’s disease: implications for treatment. Front Neurosci. 2020; 14:660.

63. Xu MY, Wong AHC. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. Acta Pharmacol Sin. 2018; 39:733–53.

64. Bi D, Wen L, Wu Z, Shen Y. GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer’s disease. Alzheimers Dement. 2020; 16:1312–29.

65. Li Y, Zhu K, Li N, Wang X, Xiao X, Li L, et al. Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. Alzheimers Res Ther. 2021; 13:114.

66. Plascencia-Villa G, Perry G. Roles of oxidative stress in synaptic dysfunction and neuronal cell death in Alzheimer’s disease. Antioxidants (Basel). 2023; 12:1628.

67. Maciejczyk M, Żebrowska E, Chabowski A. Insulin resistance and oxidative stress in the brain: what’s new? Int J Mol Sci. 2019; 20:874.

68. Vinuesa A, Pomilio C, Gregosa A, Bentivegna M, Presa J, Bellotto M, et al. Inflammation and insulin resistance as risk factors and potential therapeutic targets for Alzheimer’s disease. Front Neurosci. 2021; 15:653651.

69. Enzlein T, Lashley T, Sammour DA, Hopf C, Chávez-Gutiérrez L. Integrative single-plaque analysis reveals signature Aβ and lipid profiles in the Alzheimer’s brain. Anal Chem. 2024; 96:9799–807.

70. Torres M, Busquets X, Escribá PV. Brain lipids in the pathophysiology and treatment of Alzheimer’s disease. Davide Vito M, editor. Update on dementia. 1st ed. Rijeka: IntechOpen;2016. p. 127–67.

71. Thompson SM. Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future. Neuropsychopharmacology. 2024; 49:83–95.

72. Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019; 160:2230–42.

73. Coutinho EA, Kauffman AS. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Med Sci (Basel). 2019; 7:84.

74. Dai H, Hao C, Huang X, Liu Z, Lian H, Liu C. Different transcriptional levels of GABAA receptor subunits in mouse cumulus cells around oocytes at different mature stage. Gynecol Endocrinol. 2016; 32:1009–13.

75. Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018; 16:37.

76. Chaudhari NK, Nampoothiri LP. Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model. Horm Mol Biol Clin Investig. 2017; 29:71–7.

77. Sotomayor-Zárate R, Tiszavari M, Cruz G, Lara HE. Neonatal exposure to single doses of estradiol or testosterone programs ovarian follicular development-modified hypothalamic neurotransmitters and causes polycystic ovary during adulthood in the rat. Fertil Steril. 2011; 96:1490–6.